2512Background: U3-1402 is a human epidermal growth factor receptor 3 (HER3)-targeting antibody-drug conjugate (ADC) of high drug-to-antibody-ratio (DAR: 7 to 8) with a novel linker and topoisomerase I inhibitor payload. HER3 is overexpressed in a variety of cancers, including breast, lung, colorectal, ovarian, prostate and urothelial cancer. This ongoing, Phase 1/2 study (NCT02980341) of U3-1402 in HER3-expressing metastatic breast cancer (MBC) is divided into three parts: dose escalation (Part 1), dose finding (Part 2), and dose expansion (Part 3). Methods: In Part 1 of the ongoing study, the dose of U3-1402 was escalated based on dose-limiting toxicity data, guided by the modified Continuous Reassessment Method (mCRM). U3-1402 was administered via intravenous (IV) infusion in 21-day cycles. The primary objectives are to determine safety and tolerability of U3-1402, the maximum tolerated dose (MTD), and the recommended dose for Phase 2. AEs, PK, ORR per RECIST v1.1, and durability of responses were asse...